tusamitamab ravtansine + pembrolizumab + carboplatin + pemetrexed

This is a four-drug combination regimen consisting of **tusamitamab ravtansine** (an antibody-drug conjugate targeting CEACAM5), **pembrolizumab** (a monoclonal antibody targeting PD-1), **carboplatin** (a platinum-based chemotherapeutic), and **pemetrexed** (an antifolate chemotherapeutic). Tusamitamab ravtansine works by delivering a cytotoxic agent (DM4) directly to CEACAM5-expressing tumor cells, causing cell death. Pembrolizumab inhibits the PD-1 immune checkpoint, enhancing the anti-tumor immune response. Carboplatin induces crosslinking of DNA, leading to apoptosis, and pemetrexed inhibits several folate-dependent enzymes critical for DNA and RNA synthesis. The primary indication under investigation for this specific four-drug combination is **advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC)**, aiming to integrate immunotherapy, targeted therapy, and chemotherapy mechanisms for synergistic anti-tumor effects.